A group of Alzheimer's patients treated for 3 years with an immunotherapy drug showed no symptom decline over the treatment period. The patients were taking part in a small placebo-controlled phase 2 trial testing Baxter's intravenous immunoglobulin (IVIG) as an immunotherapy for Alzheimer's.